ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2123

Follistatin-like Protein 1 Is a Potent Regulator of Articular Chondrocytes in Osteoarthritis

Yury Chaly, Bruce Hostager, Sonja Smith and Raphael Hirsch, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: chondrocytes, extracellular matrix proteins and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Biology and Pathology of Bone and Joint - Poster I

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) is the most common degenerative disease of the joints, affecting nearly 30 million Americans. It is characterized by a change in chondrocyte phenotype. The default route of chondrocyte differentiation is terminal differentiation, hypertrophy, apoptosis, and bone formation. In healthy articular cartilage, this default route is somehow blocked to obtain permanent cartilage. In OA, this block is lifted resulting in chondrocyte terminal differentiation characterized by a decrease in production of extracellular matrix proteins (type 2 collagen and aggrecan) and an increase in production of type 10 collagen, matrix metalloproteinase 13 (MMP13), and the transcription factor Runx2. Follistatin-like protein 1 (FSTL-1) is a protein produced by articular chondrocytes. Its expression is decreased in OA. Homozygous FSTL1 knockout (KO) mice display hypocellular cartilage as well as extensive skeletal defects. We therefore sought to determine whether loss of FSTL-1 in OA contributes to disease and whether increasing FSTL-1 expression will slow or reverse OA.

Methods: FSTL-1 expression in OA and healthy human cartilage was evaluated by immunofluorescence. Cartilage was evaluated in sectioned knee joints from FSTL-1 KO mice by staining with safranin-O. In vitro experiments were performed with human articular chondrocytes immortalized with the human telomerase gene and HPV oncogenes E6 and E7. The cells were transduced with a lentivirus encoding human FSTL-1 shRNA, or with an adenovirus encoding FSTL-1. Quantitative gene expression analysis was performed using real-time PCR for MMP13, aggrecan, collagens type 2 (COL2A) and type 10 (COL10A). Protein extracts from chondrocyte pellets were analyzed for Sox9 and phospho (p)-Smad3 by Western blotting.

Results: FSTL-1 expression was reduced in the OA chondrocytes. In FSTL-1 KO mice, a marked reduction in articular cartilage cellularity, cartilage thickness, and matrix proteoglycan content was observed at 12 months of age. Downregulation of FSTL-1 expression in TGFβ-stimulated human chondrocyte pellet cultures led to abnormally small pellets with reduced proteoglycan content. The chondrocytes displayed an OA-like phenotype characterized by increased MMP13, COL10A, Runx2, and reduced Sox9, COL2A, aggrecan, and p-Smad3 expression. Transduction of chondrocytes with an FSTL-1 transgene led to a substantial increase in expression of COL2A.

Conclusion:  These studies demonstrate that FSTL-1 plays a critical role in maintaining healthy cartilage by blocking the default route of chondrocyte terminal differentiation. Furthermore, we have shown that restoring FSTL-1 expression in chondrocytes can reverse changes observed in OA.


Disclosure: Y. Chaly, None; B. Hostager, None; S. Smith, None; R. Hirsch, None.

To cite this abstract in AMA style:

Chaly Y, Hostager B, Smith S, Hirsch R. Follistatin-like Protein 1 Is a Potent Regulator of Articular Chondrocytes in Osteoarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/follistatin-like-protein-1-is-a-potent-regulator-of-articular-chondrocytes-in-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/follistatin-like-protein-1-is-a-potent-regulator-of-articular-chondrocytes-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology